A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trialShigeyoshi Iwamoto, Kensei Yamaguchi, Akira Ooki et al.|Cancer Medicine|2018Cited by 19
Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|Cancer Medicine|2020Cited by 10
Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|Cancer Medicine|2020Cited by 9
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|BMC Cancer|2022Cited by 7
Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapyShohei Udagawa, Eiji Shinozaki, Hiroki Osumi et al.|Surgery Today|2023Cited by 3